Human Insulin Market by Product Classes (Slow-Acting, Fast-Acting, Long-Acting, Intermediate-Acting and Premixed Insulin) and Forecast 2017-2021

Human Insulin Market by Product Classes (Slow-Acting, Fast-Acting, Long-Acting, Intermediate-Acting and Premixed Insulin) and Forecast 2017-2021

There are approximately 100 million people who need insulin around the world. This includes all people living with type 1 diabetes and between 20 to 30 percent of people with type 2 diabetes. Hyperglycemia or high blood sugar is a common effect of uncontrolled diabetes, which leads to serious damage to nerves and blood vessels over time. The two major sources of insulin production are human insulin and modern insulin (insulin analogues). The human insulin market can be broken into. The recombinant human segment is being displaced by the more effective but slightly more expensive insulin analogs. The global human insulin market is highly consolidated and is dominated by three major players: Novo Nordisk, Sanofi, and Eli Lilly. Increasing global diabetic population and launch of new highly potent, cost-effective drugs in the pipeline candidates by major pharmaceutical companies are likely to boost the growth of global human insulin market.

The global human insulin market report estimates the market size (Revenue USD million – 2014 to 2021) and composition of this market in terms of five product classes such as slow-acting, fast-acting, long-acting, intermediate-acting and premixed insulin and forecasts growth trends (CAGR% – 2017 to 2021).

The global human insulin market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global human insulin market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global human insulin drugs market and included in this report are Novo Nordisk, Sanofi, Eli Lilly and Company and Shanghai Fosun Pharmaceuticals.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Product Type (cells, media, serum, vaccine, protein, instrument, etc.)
    • Source Type
    • Reagents and Consumables Type
    • Diagnostic Test
    • Indication Type
    • Technology
    • Diagnostics, Therapeutic or Surgical Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  8. Recommendations
  9. References

Insulin Market

1. Source Type
1.1. Human
1.2. Recombinant

2. Mode of Action
2.1. Short-Acting Insulin
2.2. Rapid-Acting Insulin
2.2.1. Pipeline Analysis
2.2.1.1. Afrezza
2.2.1.2. NN1218 (FIAsp)
2.3. Long-Acting Insulin
2.3.1. Pipeline Analysis
2.3.1.1. IDegLira (Xultophy)
2.3.1.2. LY2605541(Novel Basal Insulin Analog)
2.3.1.3. LY2963016 (Long Acting Basal Insulin)
2.3.1.4. MK-1293 (Sustained Release Insulin Analog)
2.3.1.5. U-300 (Toujeo)
2.4. Intermediate-Acting Insulin
2.5. Premixed Insulin

3. Company Profiles
3.1. Eli Lilly and Company
3.2. Novo Nordisk A/S
3.3. Sanofi

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish